Allogene Therapeutics, Inc. (ALLO) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Allogene Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Allogene Therapeutics, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
+10.12%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Allogene Therapeutics, Inc. actually do?
Answer:
Allogene Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company's "off-the-shelf" T cell product candidates are derived from healthy donors, aiming for faster, more reliable, and scalable delivery compared to autologous therapies. Allogene is advancing three core programs: cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (RCC), and ALLO-329 for autoimmune diseases. Leveraging gene-editing technologies like TALEN and CRISPR, the company aims to minimize graft-versus-host disease and enhance T cell persistence. With a pipeline targeting significant unmet medical needs, Allogene's strategy centers on establishing leadership in allogeneic CAR T cell therapy.
Question:
What are Allogene Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily generated from license and collaboration agreements, with potential for future product sales.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required